PET scan for metastatic breast cancer
Part of Cancer clinical trials.
This trial tests a new PET scan that uses a special tracer to find breast cancer that has spread. The scan may help doctors better see where the cancer is and guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have metastatic breast cancer that tests positive for HER2 (by IHC 3+ or FISH >2.0).
- You are generally able to care for yourself (Karnofsky score greater than 50).
- You have adequate organ function (kidney, liver, blood counts) and a heart pumping ability (LVEF) of at least 50%.
- You can lie still for the scan and are not too large for the scanner (weight under 400 pounds).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan to see how well your breast cancer is responding to neoadjuvant therapy (treatment given before surgery). The goal is to help doctors personalize your care by checking if the cancer is shrinking.
This study tests a new PET scan tracer called [68Ga]Ga-PentixaFor to see if it can better detect breast cancer that has spread. You may benefit if you have triple negative breast cancer that has come back or spread, and you are looking for more precise imaging.
This study tests a special PET scan called 68Ga-DOTATOC to see if it can find certain breast cancer cells in the body. It may help doctors better understand your cancer, especially if it has spread to the liver or bones.
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
This study tests a new PET scan tracer to show where HER2-positive breast cancer cells may be in the body. It may help doctors better “map” HER2 activity, including in people with HER2-positive or HER2-negative cancer.
This trial tests a new type of PET/CT scan that uses a special tracer (called ⁶⁸Ga-FXX489) to help find and diagnose cancers. It is for people who are strongly suspected to have cancer and want to see if this new imaging method can help their doctors learn more about their disease.
Hear when a new Angiogenic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.